Renibus Therapeutics

Renibus Therapeutics is a clinical-stage biopharmaceutical company dedicated to preventing, protecting, and improving patient outcomes in cardio-renal and metabolic diseases. Their primary focus is on developing innovative therapies that target the underlying mechanisms of these conditions. Renibus is developing treatments for conditions affecting the heart and kidneys, such as heart failure and chronic kidney disease, and metabolic disorders, including diabetes and obesity. Their lead product, RBT-1, a preconditioning agent being developed for the prevention of post-operative complications in cardiothoracic surgery. It has received both FDA Breakthrough and Fast Track Designations.

Jobs: